Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 8Ovarian Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma 2

Interventions

Cisplatin 12Gemcitabine 9Specimen Handling 6Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Drug Therapy 5toripalimab 4Platinum 4Nivolumab 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3Radiotherapy 3Immune Checkpoint Inhibitors 3sintilimab 2Ipilimumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tislelizumab 1relatlimab 1pembrolizumab 1olaparib 1fluciclovine F-18 1dehydroftorafur 1cemiplimab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Immunoglobulin G × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡